Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia

Circulation

Volumn 103, Issue 9, 2001, Pages 1191-1193

  Ridker, Paul M ^a   Rifai, Nader ^a,b   Lowenthal, Susan Pitman ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Bayer Pharmaceuticals   (United States)

Author keywords

C reactive protein; Cholesterol; Inflammation; Statins

Indexed keywords

C REACTIVE PROTEIN; CERIVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL;

EID: 0035814945     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.9.1191     Document Type: Article

References (15)

1. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
2. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
3. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsberg Cohort Study, 1984 to 1992
4. Reltionship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project
5. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
6. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
7. Direct proinflammatory effect of C-reactive protein on human endothelial cells
8. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
9. Long-term effects of pravastatin on plasma concentration of C-reactive protein
10. Effect of statins on C-reactive protein in patients with coronary artery disease
11. Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolemia: The pivotal placebo-controlled clinical trial
12. Clinical efficacy of an automated high-sensitivity C-reactive protein assay
13. Pleiotropic effects of statins
14. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
15. Cerivastatin, an HMG-CoA reductase inhibitor, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro